Monday, January 13, 2020

FW: (LML) Infolep monthly overview of new publications on leprosy - January 2020

 

Leprosy Mailing List – January 13,  2020

Ref.:   (LML)  Infolep monthly overview of new publications on leprosy - January 2020

From:  Jiske Erlings, Amsterdam, the Netherlands


Dear colleagues,

 

Happy New Year and welcome to the first Infolep newsletter of 2020.
2019 has been a productive year for Infolep. 

  • We launched the new and improved Infolep website. Finding the publications you need has become much easier. 
  • The portal now offers access to over 29,120 publications. 
  • Last year the portal was used by 26,799 visitors from 190 countries.



We would like to thank our partners American Leprosy Missions, DAHW, Damien Foundation Belgium, Fairmed, Fontilles, Fondation Raoul Follereau, Lepra, Leprosy Relief Canada and NLR for their continued support. With their help, we can continue to strive for the best possible leprosy information services in 2020!

Wishing everyone a peaceful new year!

Jiske Erlings

Infolep Coordinator
j.erlings@infolep.org

 


 

Highlighted events

 


 

World Leprosy Day - 26 January 2020
 - World Leprosy Day page on Infolep

World NTD Day - 30 January 2020 - https://worldntdday.org/

 


 

New publications

 


 

Forgotten, but not gone: the threat of leprosy.
EClinicalMedicine. 2019;16:1. Nov 27. 
Download PDF
 


Localisation atypique d'un cas de lèpre à Lomé (Togo) [Atypical Localization of a Case of Leprosy in Lomé (Togo)].
Akakpo AS, Saka B, Téclessou JN, et al. Bull Soc Pathol Exot. 2019;112(3):133–136. 
Read abstract
 


A neglected illness still present nowadays: Tuberculoid leprosy / Lepra tuberculoide, todavía presente en nuestro medio.
Berzosa-Sánchez A, Soto-Sánchez B, Cacho-Calvo JB, et al. Enferm Infecc Microbiol Clin. 2019.
Read abstract
 


Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy. 
Barbosa MDS, de Sousa IBA, Simionatto S, et al. AMB Express. 2019;9(1):201
Download PDF
 


Current updates on dental perspectives of leprosy - Revisited.
Bommanavar S, Hosmani J, Khan S, et al. Dis Mon. 2019;100918. 
Read abstract
 


Intracellular Mycobacterium leprae Utilizes Host Glucose as a Carbon Source in Schwann Cells. 
Borah K, Girardi KDCV, Mendum TA, et al. MBio. 2019;10(6):e02351-19. 
Download PDF
 


Expansion and suppressive capacity of regulatory T cells isolated from patients across the leprosy spectrum: a pilot study.
Cardona C, Vieira AP, Avancini J, et al. Microbes Infect. 2019.  
Read abstract
 


Nested PCR and the TaqMan SNP Genotyping Assay enhanced the sensitivity of drug resistance testing of Mycobacterium leprae using clinical specimens of leprosy patients. 
Chen X, He J, Liu J, et al. PLoS Negl Trop Dis. 2019;13(12):e0007946.
Download PDF
 


Correlation of Dermoscopic and Histopathologic Patterns in Leprosy - A Pilot Study.
Chopra A, Mitra D, Agarwal R, Saraswat N, et al. Indian Dermatol Online J. 2019;10(6):663–668. 
Download PDF
 


A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults. 
Duthie MS, Frevol A, Day T, et al. Vaccine. 2019.
Read abstract
 


Utility and limitations of SERODIAGNOSTIC tests in monitoring the response to treatment of leprosy patients.
Duthie M, Roferos F, Abellana J, et al. Diagnostic Microbiology and Infectious Disease, 2020.
Read abstract
 


Frequency and distribution of neglected tropical diseases in Mozambique: a systematic review.
Grau-Pujol B, Massangaie M, Cano J, et al. Infect Dis Poverty. 2019;8(1):103.
Download PDF
 


Clinical characteristics of neuropathic pain in leprosy and associated somatosensory profiles. 
Haroun O, Vollert J, Lockwood D, et al. PAIN Reports. Ovid Technologies (Wolters Kluwer Health). 2019; 4 (6) : e743.
Download PDF
 


Inequalities in health by regime of affiliation to the health system in events of obligatory notification, Colombia, 2015. Desigualdades en salud según régimen de afiliación y eventos notificados al Sistema de Vigilancia (Sivigila) en Colombia, 2015.
Hilarión-Gaitán L, Díaz-Jiménez D, Cotes-Cantillo K, et al. Biomedica. 2019;39(4):737–747. 
Download PDF
 


M. leprae HSP18 suppresses copper (II) mediated ROS generation: Effect of redox stress on its structure and function. 
Nandi SK, Chakraborty A, Panda AK, et al. Int J Biol Macromol. 2019.
Read abstract
 


Mortalidad por lepra y política sanitaria. Argentina, 1980 a 2014.
Peranovich A, Celton D. Población y Salud en Mesoamérica. 2020.
Download PDF
 


Disabilities in leprosy: an open, retrospective analyses of institutional records.
Rathod S, Jagati A, Chowdhary P. Anais Brasileiros de Dermatologia, 2019.
Download PDF
 


Leprosy and the Colonial Gaze: Comparing the Dutch West and East Indies, 1750–1950.
Snelders S, van Bergen L, Huisman F. Social History of Medicine.
Download PDF
 


Leprosy in the elderly population of an endemic state in the Brazilian Northeast (2001-2017): epidemiological scenario. 
Souza CDF, Fernandes TRMO, Matos TS, Tavares CM. An Bras Dermatol. 2019.
Download PDF
 


Current treatment guideline by the World Health Organization against leprosy: A positive focus. 
Thangaraju P, Venkatesan S. J Res Med Sci. 2019;24:95. 
Download PDF
 


A case series of pediatric leprosy.
Uikey D, Joshi R, Verma N. Indian J Paediatr Dermatol. 2020;21:66-9.
Download PDF
 


 


 

 


 

Journals & Newsletters

 


 

Disability, CBR & Inclusive Development: http://dcidj.org/

Hansenologia Internationalis: http://www.ilsl.br/revista/atual.php

Indian Journal of Leprosy: http://www.ijl.org.in/index.html

Leprosy Review: https://www.lepra.org.uk/leprosy-review
Leprosy Review Repository (1928-2001): http://leprev.ilsl.br/arquivo.php

Revista de Leprología:
http://www.leprosy-information.org/resource/revista-de-leprologia

WHO Goodwill Ambassador's Newsletter for the elimination of leprosy:
https://www.shf.or.jp/information/g/ambassador?lang=en

 


 

Websites & Services

 


 

WHO Global Leprosy Programme
https://www.who.int/lep/en/

The Global Partnership for Zero leprosy
http://zeroleprosy.org/

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in this theme to share ideas, information, experiences, and questions.
https://groups.google.com/forum/#!forum/leprosymailinglist

Fontilles y la lepra en España / Fontilles and leprosy in Spain
http://www.cervantesvirtual.com/portales/fontilles_y_la_lepra_en_espana/

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)
https://www.infontd.org/



 

 


 

GDPR & the Infolep newsletter

 


 

New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regard to the GDPR, including our privacy statement and mailing list. Infolep sends out monthly e-mails to its subscribers with an overview of recent publications on leprosy. The purpose of this activity is to keep subscribers up to date. Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else. We hope the content from the Infolep newsletter is useful to you, but you can update your preferences or unsubscribe from this list at any time.

 



LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/bed521d6-a86f-4504-b039-370c25cbbf4b%40googlegroups.com.

Friday, January 10, 2020

FW: (LML) (LML) Dapsone allergy and MB treatment

 

 

Leprosy Mailing List – January 10,  2020

Ref.:  (LML)   (LML) Dapsone allergy and MB treatment

From:  Joel Almeida, London and Mumbai


 

Dear Pieter & colleagues,

 

Dr. Shen Jianping (LML 6 Jan 2020) wrote:

 

"28 % of new leprosy patients, most were MB patients, are treated with only two drugs, rifampicin and clofazimine for one year. We do not know if there is a risk for treatment failure.  A paper from Yunnan province, China, reported that the BI declined very slowly among patients with 1301 gene-locus positivity, and treated with only two drugs."

 

There is indeed likely to be a risk of treatment failure with 1 year of anti-microbial treatment among those LL patients in Yunnan who have only monthly rifampicin and unsupervised ingestion of daily clofazimine at about 1 mg/kg/day. This risk is greater among "slow responders" who tend to be diagnosed with a high BI at all sites, dense AFB globi in macrophages, negative lepromin response and relatively high T-reg cell frequency. In multi-patient families/households with "slow responders", the risk of treatment failure is likely to be greater still. That is because even recessive genes contributing to increased risk can combine in homozygous offspring. Such patients with genetically-linked reduction in specific immunity tend to remain susceptible to HD bacilli. This multiplied risk might well occur even in Yunnan where new patients are more markedly clustered than in many other places. Further, sources of infection/re-infection are likely to be even higher in zones where BCG vaccination coverage has not yet reached 100% in all age groups, or BCG re-vaccination is not given to household contacts.

 

It is worth noting that the risk of recurrence (by treatment failure/relapse or re-infection) among LL patients tends to be under-estimated:

 

a) if inexpert clinical examination is relied on for diagnosis of recurrence. Expert clinicians compared to even well-trained but inexpert staff diagnose recurrence as much as 3 times (300%) more frequently/promptly. Delayed recognition of recurrence is accompanied by the risk of transmission as well as of nerve damage, pain and permanent disfigurement. 

 

b) if follow-up of patients released from treatment is discontinued within 5 years, since most clinically diagnosed recurrences occur in years 6 and later after release from treatment.

 

c) if years 0-5 after RFT (lower-risk years) are included in the denominator, thus disguising the risk in years 6 and later.

 

d) if patients without LL anergy are included in the denominator, thus disguising the risk in patients with anergy.

 

 

Implications for action

 

The treatment recommendation of the US HD program is probably more reliably effective than other recommendations, especially for countries that have a reputation for being global leaders in public health. This involves daily anti-microbial treatment of LL or BL HD for minimum 24 months, if necessary replacing dapsone with minocycline or a fluoroquinolone. The benefits of reliable cure and near-zero transmission are so great that the necessary investment might be considered a good bargain.

 

The occasional new diagnosis of HD in a child in Yunnan suggests that sources of infection have not entirely been stopped. For the purpose of ensuring consistent cure and more rapidly reaching near-zero transmission, the following may be considered:

 

= = = = = 

 

Serological examination of contacts (to exclude disease) for every known current or past MB patient, and also serology for the current/past MB patients themselves.

 

1. If serologically positive, then full expert clinical examination and full diagnostic panel of tests for HD. Including slit skin smear, skin biopsy histopathology, nerve conduction.

 

If HD confirmed, treatment according to the recommendations of the US HD program.

 

a) MB regimen or 

b) PB regimen 

(replacing dapsone when necessary rather than merely omitting it)

 

Also,

c) regular monitoring and treatment of any complications / drug adverse effects.

d) In prefectures where any child patients were diagnosed within the past 5 years, all LL patients could be given post-MDT chemoprophylaxis (monthly rifampicin + moxifloxacin + minocycline) to protect them against re-infection.

 

 

2. In the remaining contacts/former patients, presumed now to be free from disease -

vaccination with BCG (or MIP vaccine) plus multi-drug chemoprophylaxis (eg., rifampicin + moxifloxacin + minocycline one dose). Multi-drug combinations, unlike single drug use, reduce the risk of selecting drug-resistant mutants.

 

Further, all newly diagnosed patients and all patients with recurrent HD could be monitored for drug resistance, especially rifampicin resistance. That is because some highly bacillated patients given only rifampicin + unsupervised clofazimine may show an increased frequency of drug-resistant mutant bacilli. 

 

= = = = =

 

This approach has a high likelihood of not only protecting all diagnosed HD patients, including those with HLA-B*1301, but also accelerating the decline of HD new patients in Yunnan from 10%/year to 20+% per year. This will match or exceed the success of Weifang/Shandong in rapidly achieving near-zero transmission.  


Hope that helps. LML's many experts might wish to make further suggestions. It will be interesting to follow what happens in Yunnan. Near-zero transmission might be achieved relatively rapidly, even before GDP per capita expands to affluent levels. A lot of useful work has already been done. Best wishes to Dr. Shen and other great colleagues in China.

 

 

Joel Almeida

 

 

P.S. An early analysis of bacillary sub-populations during treatment of HD is given in: 

Almeida, JG. A Quantitative Basis for Sustainable Anti-Mycobacterium leprae Chemotherapy in Leprosy Control Programs. Int J Lepr (1992) 60(2):255-268.  This offers only part of the picture. Long-term (eg., 20 year-plus) follow-up of LL patients can give definitive answers, especially because recurrence can be difficult to diagnose promptly in LL patients.


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/64fa623c-728e-4f12-bd94-2c6222372b6d%40googlegroups.com.

Wednesday, January 8, 2020

FW: (LML) Call for submission – Visit to Japan, 12 to 19 February 2020

 

 

Leprosy Mailing List – January 8,  2020

Ref.:   (LML)  Call for submission – Visit to Japan, 12 to 19 February 2020

From:  Alice Cruz, Quito, Equator


Dear Pieter and colleagues,

The United Nations Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members, Ms. Alice Cruz, will undertake an official country visit to Japan from 12 to 19 February 2020, to examine in situ questions related to the human rights of persons affected by leprosy and their family members.

In this context, the Special Rapporteur is looking for information related to her mandate, amongst others:

  • Identification of the manifestations of discrimination against persons affected by leprosy and their family members as well as other relevant issues such as preservation of history, reparation measures, healthcare of foreign-born cases and international cooperation.
  • Identification of stakeholders including authorities and civil society to meet with;
  • Key issues and challenges faced in the implementation of the international and regional legal framework on leprosy and disabilities;
  • Good practices aimed at promoting the protection of the human rights of persons affected by leprosy and their family members, including legal or administrative measures and awareness-raising activities, 
  • Any other pertinent information that you consider to be relevant for the visit of the Special Rapporteur.

Please feel free to send any written material (in English, French or Spanish) to srleprosy@ohchr.org

Your contribution will be kept confidential.

https://www.ohchr.org/EN/Issues/Leprosy/Pages/CallJapan.aspx


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/52ba6f50-7297-4821-a464-a6d85ca270b3%40googlegroups.com.

Monday, January 6, 2020

FW: (LML) Dapsone allergy and MB treatment

 

Leprosy Mailing List – January 6,  2020

Ref.:   (LML) Dapsone allergy and MB treatment

From:  Shen Jianping, Nanjing, China


Dear Dr Pieter Schreuder,

 

Happy New Year 2020. 

 

I have a question about MB leprosy treatment in China. Now in China, all newly detected leprosy patients are checked for dapsone allergy, 1301 gene-locus for possible DDS syndrome.

 

The 1301 gene-locus positivity among the newly detected patient is 28%, but in past the incidence of Dapsone syndrome was only 2-3% each year in China. That means that 28 % of new leprosy patients, most were MB patients, are treated with only two drugs, rifampicin and clofazimine for one year. We do not know if there is a risk for treatment failure.  A paper from Yunnan province, China, reported that the BI declined very slowly among patients with 1301 gene-locus positivity, and treated with only two drugs. 

 

I remember that WHO once recommended that a leprosy patient with dapsone allergy can be treated with two drugs only, rifampicin and clofazimine. This recommendation is still effective now? In 2018, WHO recommended that PB patients would be treated with 3 drugs, but we now use only two drugs to treat MB leprosy.  

 

Thank you and all for your suggestions and advice,

 

Dr Shen Jianping 

 

Professor, National Center for Leprosy Control

Nanjing PR China 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/750f0a5c-d208-4d72-aad9-343bda863f3b%40googlegroups.com.

Sunday, January 5, 2020

FW: (LML) Rapid, open scientific discourse for improved outcomes

 


Leprosy Mailing List – January 5,  2020

Ref.:  (LML)   Rapid, open scientific discourse for improved outcomes

From:  Joel Almeida, London and Mumbai


Dear Pieter and colleagues,

 

Richard Smith, formerly editor of the British Medical Journal, has reasonably well-informed insights about the scientific method and the role of traditional publication. Printed journals stored in physical libraries were once the only option. However, Smith in 2006 described what he considered to be a preferable approach:

 

"Open up the whole process and conduct it in real time on the web in front of the eyes of anybody interested. Peer review would then be transformed from a black box into an open scientific discourse." (1)

 

What prompted Smith to take this view?

 

In his words: "the phrase `peer reviewed journal' is supposed to guarantee quality. But clearly peer review is deficient. Despite being central to the scientific process it was itself largely unstudied until various pioneers—including Stephen Lock, former editor of the BMJ, and Drummond Rennie, deputy editor of JAMA—urged that it could and should be studied. Studies so far have shown that it is slow, expensive, ineffective, something of a lottery, prone to bias and abuse, and hopeless at spotting errors and fraud. The benefits of peer review have been much harder to establish. As Rennie says, `If it was a drug it would never get onto the market'." (1)

 

Traditional journals, despite all their merits, too often have sheltered errors unintentionally. That's because it's easier for 2 reviewers inadvertently to overlook errors than for hundreds of experts to fall short in this way. The results section of most papers is often reasonably reliable. However, even when the methods are sound, the introduction and the discussion sections allow considerable latitude for error. Thereafter, the paper can gather dust on a shelf and its flaws can remain unnoticed and uncorrected. That is why it is important to look behind the abstract or the introduction /discussion /conclusions and examine the raw observations in any paper of consequence.

 

 

Scientific method vs extraneous considerations

 

Non-scientific criteria can sometimes creep into scientific discussions. For example, if we go back in history we come to Galileo and his claim that the earth revolved around the sun. How did the traditionalists respond to his work "Dialogue concerning the Two Chief World Systems" (3)? They asserted that the typeface of Galileo's work was inappropriate, and the organisation of his document was different from a scientific book. These objections were extraneous to the scientific method. They are similar to discussions about where something is written. Galileo had the truth. In the end, only the truth works.

 

The scientific method clearly is indispensable to science. The traditional journal, despite its unique role in the pre-internet era, is less so. We need to keep faith with the scientific method: conjecture and refutation.(4) But traditional journals are no longer the only available channel in the internet age. Further, traditional journals as well as other channels are reliable only to the extent that they weed out error.

 

Meetings too can play a useful role, although the travel and time involved tend to limit participation compared to online discussions. At a meeting of the German Paediatric Society at Kassel in October 1960, Kosenow and Pfeiffer presented evidence of two infants showing malformations. It would have been unwise and dangerous to neglect this first report of the apparent adverse effects of thalidomide in pregnant women merely because it was made outside a traditional journal. Typefaces, venues etc are not part of the scientific method. It seems wise to rely on the scientific method and not on extraneous considerations.

 

 

Solutions

 

LML, like Gates Open Research,  Wellcome Open ResearchUCL Child Health Open Research, enables rapid publication of contributions that are exposed to open scientific discourse of the sort described by Smith.(1) The author(s) can then reconsider, refine and correct their analysis. This interactive cycle progressively and relatively rapidly eliminates errors. On LML, contributions are read (and substantive disagreements, if any, identified) by a larger set of knowledgeable experts than just the 2 reviewers typical of traditional journals. That is why errors tend to have such a short half-life on LML. As a result, the truth emerges more rapidly in such online channels than almost anywhere else. The Gates Foundation and the Wellcome Trust are not naive in their choice of publishing strategy. They reinforce the direction of travel.

 

Traditional journals are also characterised by slowness. The sheer speed of the LML process is unrivalled. Decisions on contributions are made in days, not months (or sometimes even two and a half years in one case involving an HD journal, which ultimately still failed to reach a clear decision). Time is of the essence because human nerves, limbs, eyes, minds, livelihoods and relationships are at stake.

 

LML contributions are probably the most widely read in the HD world, partly because everyone has a voice here and can put forward substantive points immediately. The contributions can then be stored, displayed and searched online for anyone to view. They can be, and have been, cited in some of the most fastidious traditional journals. If and when fashions steer us towards a cliff, such open forums sometimes can help remind us of the difference between right and might. As a result, we are less likely to expose the people we serve to unnecessary harm.  

 

Evolution of effective policy has always benefited from wide discussion. This was true even before the internet. In the UK, such wide discussion is now required by the National Institute of Health Care and Clinical Excellence (NICE) before guidance can be issued. The NICE process is more open and error-resistant than some others. Discussion in the NICE process is carried on outside the traditional journals. After NICE guidance is issued, it is kept under constant review as new information surfaces. In this way, harmful guidance is weeded out and effectiveness is constantly maintained or even boosted. In HD, LML is the nearest we have to the NICE process for improving effectiveness and outcomes.  

  

 

A brighter future

 

Having been in the thick of the struggle to help transform TB from a neglected disease in the early '90s to a major global issue with boosted financing and life-saving outcomes, I believe that the kind of pragmatic action-oriented analysis often found on LML is likely to be reasonably impactful. As my mentor the great Dr. Kochi used to say at WHO, "Make complex things simple if you want great outcomes." At the Global TB Programme we relied on well-researched, persuasive reports that were often acted on by health ministries, finance ministries, planning commissions, foreign aid departments, the World Bank, NGOs, private physicians and the media. The real world is messy, and we must still discern the few critical actions that enable great outcomes. 

 

Fortunately, we are a compassionate community with a clear memory of why we are involved with HD at all. We have tasted real success and now it is unlikely that we will settle for less. Since Shandong and Uele achieved 17% to 20%/year declines in HD, so can we. Since the Brazilian programme and roving paramedical workers in Dadra Nagar Haveli (India) monitor nerve function regularly, so can we. Since the world considers it important to protect vulnerable people from unintended adverse effects, so can we. LML helps all this greatly. 

 

Joel Almeida

 

References

 

1. Smith, R. Peer review: a flawed process at the heart of science and journals. J R Soc Med. 2006 Apr; 99(4): 178–182.doi: 10.1258/jrsm.99.4.178

 

2. Peters D, Ceci S. Peer-review practices of psychological journals: the fate of submitted articles, submitted again. Behav Brain Sci 1982;5: 187-255

 

3.  Galileo Galilei, Stephen Jay Gould (Editor), Stillman Drake (Translator), Albert Einstein (Foreword), J.L. Heilbron (Introduction). Dialogue Concerning the Two Chief World Systems. Modern Library, 2001. translated from: Dialogo sopra i due massimi sistemi del mondo. Florence, 1632.

 

4. Popper, K. Conjectures and Refutations: The Growth of Scientific Knowledge. Routledge; second edition, 2 May 2002


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/f326cfaf-ec33-498d-9526-2007de37c770%40googlegroups.com.

Saturday, January 4, 2020

FW: (LML) Leprosy Review Index


 

Leprosy Mailing List – January 4,  2020

Ref.:   (LML) Leprosy Review Index

From:  Pieter Schreuder, Maastricht, the Netherlands


Dear colleagues,

 

In this first LML letter of 2020, may we extend to all of you our best wishes for 2020.


It is not always easy to keep up to date with all new developments. The monthly INFOLEP selection offers you a wide variety of studies and articles. Also,one could scan the contents list of Leprosy Review (https://www.lepra.org.uk/leprosy-review-index).  Like the Indian Journal of Leprosy, one of the few leprosy related journals in English. LML tries to be a critical voice, not all official publications should be taken at face value.


Here an example of the contents of Leprosy Review:


Volume 90, Number 4, December 2019


Contents

Editors Choice - December 2019 P. Saunderson


Original Papers

356 Leprosy post-exposure prophylaxis with single dose rifampicin: toolkit for implementation T.Barth-Jaeggi, A.Cavaliero, A.Aerts, S. Anand, S.Sarady Ay, T.M Aye, N.L. Banstola, R.Baskota, D. Blaney, M. Bonenberger, W.Van Brakel, H.Cross, V.K Das, T. Budiawan, N. Fernando, Z. Gano, H. Greter, E.Ignotti, D.Kamara, C.Kasang, B.Komm, A. Kumar, S.Lay, L.Mieras, F.Mirza, B.Mutayoba, B.Njako, T.Pakasi, J.Hendrick Richardus, P.Saunderson, C.S Smith, R.Staheli, N.Suriyaracharchi, T.Shew, A.Tiwari, M.S.D, Wijesinghe, J.V Berkel, B.V Plaetse, M.Virmond and P.Steinmann.

364 Ultrasonography versus clinical examination in detecting leprosy neuropathy M.S.Kumaran, M. Thapa, T.Narang, M.Prakash and S.Dogra

371 Case-control study measuring the association between HLA-B*13:01 and dapsone hypersensitivity syndrome in Indian patients M.J. Chiramel, R.George, D.Daniel, R.S.A Das, V.Mani, B. Antonisamy and J.P Muliyil

378 Odontogenic infections and leprosy reactions:  A case-control study D.C.B. Cortela, M.R.S. Nogueira, A.L De Souza Junior and E.Ignotti

388 Levels of disability and relapse in Bangladesh MB leprosy cases, 10 years after treatment with 6m MB-MDT C.R. Butlin, K.J. Maug Aung, S. Withington, P.Nicholls K.Alam

399 An exploration into the psychological impact of leprosy in Sirajganj, Bangladesh A. Bow Betrand, D.Pahan and J.Mangeard-Lourme

418 Community stigma and desired social distance towards people affected by leprosy in Chandauli District, India A.V Ballering, R.M.H. Peters, M.M. Waltz, M.A. Arif, C.P. Mishra and W.H. Van Brakel

433 The challenge of health seeking: recollections of leprosy inpatients in post-elimination Nepal U-B. Engelbrektsson, M.Subedi and P.Nicholls


Case Reports

444 Borderline Tuberculoid leprosy of the scalp mimicking alopecia areata-vitiligo overlap syndrome: A case report S.Sharma, S.Dayal, C.Bansal, Janshruti, K. Aggarwal and N.Marwah

450 Melioidosis complicating lepromatous with type 2 lepra reactions: A rare case report from India S.Pradhan, A.N Rout, C.S Sirka, S.K Das and K.Sahu

456 Successful treatment of rifampicin resistant case of leprosy by WHO recommended ofloxacin and minocycline regimen M.Lavania, J.Darlong, A.Reddy, M.Ahuja, I.Singh, R.P Turankar and U.Sengupta

460 Treatment of leprosy wounds with ''Jinchuang ointment'', a traditional Chinese herbal medicine complex W.-H Hsu. Tsai, S.-J.Hung, H.-C. Cheng, C-H. Hsu, T-J. Ho and H-P. Chen

469 Bullous erythema nodosum leprosum: a rare case series S.Pradhan, A.Nibedita Rout, C.Sekhar Sirka, K.Sahu and G.Dash

476 Clinical and histopathological profile of a patient with localized lepromatous leprosy J.Jose, L.Das, P.A. Singh and R.Marshala

482 Reflections on the 20th International Leprosy Congress held in Manila, from Sept 10th to 13th, 2019


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/3bf353b4-1775-4172-b388-b1dee76a83a7%40googlegroups.com.